Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck’s Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014
Dateline City:
WHITEHOUSE STATION, N.J.
Exploratory Analyses in Advanced Melanoma and NSCLC Presented in Oral Session
Dr. Roger Perlmutter to Present at AACR Opening Plenary Session
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of early findings from studies
exploring the relationship between tumor PD-L1 expression and clinical
outcomes following monotherapy treatment with MK-3475, an
investigational anti-PD-1 immunotherapy, in patients with advanced
melanoma and advanced non-small cell lung cancer (NSCLC).
Language:
English
Contact:
Media:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Melanoma | Merck | Non-Small Cell Lung Cancer | Oral Cancer | Pharmaceuticals | Skin Cancer | Study